|Day Low/High||94.87 / 95.67|
|52 Wk Low/High||62.55 / 101.28|
Covid-19 has had a big impact on this sector, but these names have strong catalysts going into the next quarter.
There is no thought of selling here and now, even with politicized pressure on the industry.
Plus, it could be quite a while before the labor market can absorb all those people who are out of jobs.
These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.
I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.
Here's an updated strategy for ABBV, which could see new highs soon.
I have always liked the aggressive management.
A lifting on the moratorium on elective procedures could be a big win for ABBV.
What's really driving the market, what's making the Nasdaq roar? Tech and science, that's what.
The market sold off on Thursday after close as big hitters, including Amazon, reported earnings.
When it's beaten you will wish you own stocks, especially the stocks that are right now lethal to your portfolio.
After a company reports we all know what's wrong, it's immunized. And that's when you can buy.
JNJ should survive a recession and prove in demand in a health crisis.
Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.
Here are six companies that should come through in the tough times ahead.
You can use these wild market swings to your advantage by identifying 'safe' companies you want to own and then buying their stocks in stages.
But don't throw up your arms yet -- here are names that could be golden opportunities.
This is the time to high grade your portfolio, take some losses and move to better stocks.
Let's review the charts and indicators.
For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.
Newly confirmed cases of the Covid-19 virus spiked from Hubei Province in China, where the city of Wuhan is located. The number of related deaths increased as well.
This rally has been industry, not sector led, and it is all based on technology, whether or not market leaders reside within the Tech sector or not.
Merger activity is the number 1 driver I am watching for biotech growth.
I'm watching the shares of Estee Lauder, Disney and Amazon.
AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.
I think, ultimately, the big issue for many will be what happens in the United States if we hear about people who didn't go to China who have come down with the disease.
Nobody in AbbVie right now is in it for the past performance.